Literature DB >> 18430151

The role of testosterone in the pathogenesis of prostate cancer.

Takashi Imamoto1, Hiroyoshi Suzuki, Masashi Yano, Koji Kawamura, Naoto Kamiya, Kazuhiro Araki, Akira Komiya, Naoki Nihei, Yukio Naya, Tomohiko Ichikawa.   

Abstract

Relationships between androgenic hormones and prostatic tissue growth are complex. It is certainly true that the prostate will not develop without androgens and the gland will atrophy if androgen support is withdrawn. The hormonal hypothesis remains one of the most important hypotheses in the etiology of prostate cancer (PCa), and efforts are continuing to improve the understanding of androgen actions in PCa. Although evidence from epidemiological studies of associations between circulating levels of androgens and PCa risk has been inconsistent, the traditional view that higher testosterone (T) levels represent a risk factor for PCa appears to have little evidentiary support. Reinvestigation of the relationship between T and PCa seems important and necessary if a new, clinically and scientifically rewarding concept is to be constructed. The present review considers the metabolism and intraprostatic action of T, epidemiological evidence, and the association between T and PCa risk.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18430151     DOI: 10.1111/j.1442-2042.2008.02074.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  25 in total

1.  The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy.

Authors:  Luis A Kluth; Shahrokh F Shariat; Christian Kratzik; Scott Tagawa; Guru Sonpavde; Malte Rieken; Douglas S Scherr; Karl Pummer
Journal:  World J Urol       Date:  2013-09-03       Impact factor: 4.226

Review 2.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

Authors:  William P Harris; Elahe A Mostaghel; Peter S Nelson; Bruce Montgomery
Journal:  Nat Clin Pract Urol       Date:  2009-02

3.  Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading.

Authors:  A Pichon; Y Neuzillet; H Botto; J-P Raynaud; C Radulescu; V Molinié; J-M Herve; T Lebret
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-10-06       Impact factor: 5.554

Review 4.  COVID-19 and androgen-targeted therapy for prostate cancer patients.

Authors:  Neil A Bhowmick; Jillian Oft; Tanya Dorff; Sumanta Pal; Neeraj Agarwal; Robert A Figlin; Edwin M Posadas; Stephen J Freedland; Jun Gong
Journal:  Endocr Relat Cancer       Date:  2020-09       Impact factor: 5.678

5.  Genome-wide association study identifies a new locus JMJD1C at 10q21 that may influence serum androgen levels in men.

Authors:  Guangfu Jin; Jielin Sun; Seong-Tae Kim; Junjie Feng; Zhong Wang; Sha Tao; Zhuo Chen; Lina Purcell; Shelly Smith; William B Isaacs; Roger S Rittmaster; S Lilly Zheng; Lynn D Condreay; Jianfeng Xu
Journal:  Hum Mol Genet       Date:  2012-08-30       Impact factor: 6.150

Review 6.  Targeting 5α-reductase for prostate cancer prevention and treatment.

Authors:  Lucas P Nacusi; Donald J Tindall
Journal:  Nat Rev Urol       Date:  2011-05-31       Impact factor: 14.432

7.  Racial Differences in Age-Related Variations of Testosterone Levels Among US Males: Potential Implications for Prostate Cancer and Personalized Medication.

Authors:  Hui Hu; Folakemi T Odedina; Romonia R Reams; Claudia T K Lissaker; Xiaohui Xu
Journal:  J Racial Ethn Health Disparities       Date:  2014-09-11

8.  Circulating sex steroids and prostate cancer: introducing the time-dependency theory.

Authors:  Andrea Salonia; Firas Abdollah; Umberto Capitanio; Nazareno Suardi; Andrea Gallina; Giulia Castagna; Maria Chiara Clementi; Alberto Briganti; Patrizio Rigatti; Francesco Montorsi
Journal:  World J Urol       Date:  2013-01-03       Impact factor: 4.226

9.  Urological second malignant neoplasms in testicular nonseminoma survivors: a population-based analysis.

Authors:  Hao Li; Chenxing Zhu; Jiapei Wu; Yuchen Ma; Xi Jin; Xin Wei; Kunjie Wang; Hong Li
Journal:  Int Urol Nephrol       Date:  2020-10-14       Impact factor: 2.370

Review 10.  Current topics and perspectives relating to hormone therapy for prostate cancer.

Authors:  Hiroyoshi Suzuki; Naoto Kamiya; Takashi Imamoto; Koji Kawamura; Masashi Yano; Makoto Takano; Takanobu Utsumi; Yukio Naya; Tomohiko Ichikawa
Journal:  Int J Clin Oncol       Date:  2008-10-23       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.